According to the advisory, alcohol is the “third leading preventable cause” of cancer in the US, following tobacco use and obesity. It underscored that alcohol consumption contributed to cancers of ...

said that alcohol was the third most common preventable cause of cancer after tobacco and obesity. "The direct link between alcohol consumption and cancer risk is well-established for at least ...

NEW LISBON, Wis. (WFRV) – Authorities are actively searching for a 47-year-old man identified as a person of interest in the deaths of a 33-year-old woman and her two children in New Lisbon.

Beginning in early 2025, Ghana is allowing visa free entry to citizens of all countries in Africa, after president Nana Akufo-Addo gave the move the green light in December. It comes after a ...

Wia dis foto come from, Ghana National Fire Service/Facebook Fire outbreak happun for Kantamanto market for Accra, Ghana, for di early hours of Thursday, and destroy ova 100 shops. Di fire wey ...

Objective The objective of this study was to determine the prevalence and predictors of overweight and obesity in Burkina Faso using a population-based countrywide sample. We hypothesise that there is ...

Two people were arrested after an argument on social media turned into a fight and later a stabbing on New Year’s Eve, resulting in one person being taken to the hospital with non-life ...

Credit: Andrey_Popov via Shutterstock. Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most ...

Credit: Ciara Kimsey / Shutterstock. Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

2. Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication. 3.